Opinion|Videos|July 26, 2024
Cilta-cel in R/R MM: ASCO 2024 Updates from CARTITUDE Trials
Hans Lee, MD, discusses recent updates presented at ASCO 2024 surrounding cilta-cel CAR T-cell therapy in relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Review the recent updates surrounding CAR T-cell therapy in R/R MM:
- CARTITUDE-4 subgroup analysis
- CARTITUDE-2 cohort A expansion subgroup
- CARTITUDE-2 cohort D
- What is the rationale for using CAR T-cell therapy in patients with R/R MM?
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Matthew J. Frigault, MD, and Adam D. Cohen, MD, discuss guidelines, 5-year data, sequencing, and referral practice for cellular therapy in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
2
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
3
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
4
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?
5